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Long term tapering versus standard prednisolone treatment for 
first episode of childhood nephrotic syndrome: phase III  
randomised controlled trial and economic evaluation
Nicholas J A Webb,1,2 Rebecca L Woolley,3 Tosin Lambe,4 Emma Frew,4 Elizabeth A Brettell,3 
Emma N Barsoum,3 Richard S Trompeter,5 Carole Cummins,6 Jonathan J Deeks,3,7  
Keith Wheatley,8 Natalie J Ives,3 On behalf of the PREDNOS Collaborative Group
ABSTRACT
OBJECTIVE
To determine whether extending initial prednisolone 
treatment from eight to 16 weeks in children with 
idiopathic steroid sensitive nephrotic syndrome 
improves the pattern of disease relapse.
DESIGN
Double blind, parallel group, phase III randomised 
placebo controlled trial, including a cost effectiveness 
analysis.
SETTING
125 UK National Health Service district general 
hospitals and tertiary paediatric nephrology centres.
PARTICIPANTS
237 children aged 1-14 years with a first episode of 
steroid sensitive nephrotic syndrome.
INTERVENTIONS
Children were randomised to receive an extended 16 
week course of prednisolone (total dose 3150 mg/m2)  
or a standard eight week course of prednisolone 
(total dose 2240 mg/m2). The drug was supplied 
as 5 mg tablets alongside matching placebo so 
that participants in both groups received the same 
number of tablets at any time point in the study. A 
minimisation algorithm ensured balanced treatment 
allocation by ethnicity (South Asian, white, or other) 
and age (5 years or less, 6 years or more).
MAIN OUTCOME MEASURES
The primary outcome measure was time to first relapse 
over a minimum follow-up of 24 months. Secondary 
outcome measures were relapse rate, incidence of 
frequently relapsing nephrotic syndrome and steroid 
dependent nephrotic syndrome, use of alternative 
immunosuppressive treatment, rates of adverse 
events, behavioural change using the Achenbach 
child behaviour checklist, quality adjusted life years, 
and cost effectiveness from a healthcare perspective. 
Analysis was by intention to treat.
RESULTS
No significant difference was found in time to first 
relapse (hazard ratio 0.87, 95% confidence interval 
0.65 to 1.17, log rank P=0.28) or in the incidence of 
frequently relapsing nephrotic syndrome (extended 
course 60/114 (53%) v standard course 55/109 
(50%), P=0.75), steroid dependent nephrotic 
syndrome (48/114 (42%) v 48/109 (44%), P=0.77), 
or requirement for alternative immunosuppressive 
treatment (62/114 (54%) v 61/109 (56%), P=0.81). 
Total prednisolone dose after completion of the trial 
drug was 6674 mg for the extended course versus 
5475 mg for the standard course (P=0.07). There 
were no statistically significant differences in serious 
adverse event rates (extended course 19/114 (17%) 
v standard course 27/109 (25%), P=0.13) or adverse 
event rates, with the exception of behaviour, which 
was poorer in the standard course group. Scores on 
the Achenbach child behaviour checklist did not, 
however, differ. Extended course treatment was 
associated with a mean increase in generic quality 
of life (0.0162 additional quality adjusted life years, 
95% confidence interval −0.005 to 0.037) and cost 
savings (difference −£1673 ($2160; €1930), 95% 
confidence interval −£3455 to £109).
CONCLUSIONS
Clinical outcomes did not improve when the initial 
course of prednisolone treatment was extended from 
eight to 16 weeks in UK children with steroid sensitive 
nephrotic syndrome. However, evidence was found of 
a short term health economic benefit through reduced 
resource use and increased quality of life.
TRIAL REGISTRATION
ISRCTN16645249; EudraCT 2010-022489-29.
Introduction
Idiopathic nephrotic syndrome is the commonest 
childhood glomerular disorder, with an annual 
WHAT IS ALREADY KNOWN ON THIS TOPIC
More than 90% of children who present with idiopathic nephrotic syndrome 
respond to a course of high dose oral corticosteroid, and current practice is to 
treat most patients with prednisolone
The Kidney Disease: Improving Global Outcomes 2012 treatment guidelines 
recommended that prednisolone be administered daily for four to six weeks 
followed by alternate daily for two to five months—this recommendation was 
based on six trials that were reported before the start of the PREDNOS trial, 
although all had methodological problems
Most UK centres and many other countries continue to use the standard eight 
week course of prednisolone first described by the International Study of Kidney 
Disease in Children in the 1960s
WHAT THIS STUDY ADDS
An extended initial 16 week course of prednisolone treatment in UK children 
with steroid sensitive nephrotic syndrome did not improve the pattern of disease 
relapse compared with those who received the standard eight week course
Extended course prednisolone treatment reduced healthcare resource use in the 
first two years and made a small improvement in quality of life
Concerns about adverse events from exposing children to extended prednisolone 
treatment were not supported
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incidence of two per 100 000 children in the United 
Kingdom. Children present with the disease at a 
median age of 2-3 years, and it is twice as common in 
boys and four to six times more common in people of 
South Asian origin.1-4
More than 90% of children who present with 
idiopathic nephrotic syndrome respond to a course 
of high dose corticosteroid treatment, and current 
practice is to treat most patients empirically with 
prednisolone.5 6 Children who respond to treatment are 
given a diagnostic label of steroid sensitive nephrotic 
syndrome and generally have a good prognosis with a 
low incidence of end stage renal disease.
After initial successful treatment, around 80% of 
children with steroid sensitive nephrotic syndrome have 
disease relapses requiring further courses of high dose 
prednisolone. About 50% develop frequently relapsing 
nephrotic syndrome (two or more relapses within six 
months of presentation or four relapses within any 
12 months) or steroid dependent nephrotic syndrome 
(relapse while receiving prednisolone or within 14 days 
of stopping the drug).7 Relapses and further high dose 
prednisolone treatment are associated with substantial 
morbidity.8 When complications develop or are 
anticipated after repeated courses of corticosteroids, 
alternative immunosuppressive treatment is indicated, 
such as levamisole, cyclophosphamide, ciclosporin, 
tacrolimus, mycophenolate mofetil, or rituximab.
The best initial prednisolone regimen for children 
presenting with steroid sensitive nephrotic syndrome 
remains unknown. The eight week course first 
described in the 1960s by the International Study of 
Kidney Disease in Children (prednisolone 60 mg/m2 
for four weeks then 40 mg/m2 on alternate days for 
four weeks) continues to be used in most UK centres 
and in many other countries. However, systematic 
review data suggest that a more intensive initial 
treatment course improves clinical outcomes.9 When 
the prednisolone in nephrotic syndrome (PREDNOS) 
trial started, six randomised controlled trials had 
compared the eight week course with a range of 
different prednisolone regimens of three months or 
longer.10-15 A 2005 Cochrane review concluded that 
prednisolone treatment of three months or longer 
statistically significantly reduced the rate of relapse 
at 12-24 months and the rate of frequently relapsing 
nephrotic syndrome.16 The Kidney Disease: Improving 
Global Outcomes guidelines published in 2012 
supported the conclusions of this Cochrane review. 
These guidelines recommended daily prednisolone 
treatment of 60 mg/m2 or 2 mg/kg for four to six weeks 
followed by 40 mg/m2 or 1.5 mg/kg on alternate days 
and continued for two to five months, with tapering of 
the dose.17 Despite these recommendations, several 
methodological concerns relating to these six studies 
have resulted in the continued use of the eight week 
course in the UK and elsewhere.
We conducted the PREDNOS trial to compare this 
eight week course with a longer 16 week course in UK 
children. The study design was optimised to overcome 
the methodological concerns relating to previous 
studies. We first performed an external pilot study over 
a year that included 55 participants. This pilot study 
helped us to develop the design of the main trial and 
found that participants of different ethnicities could be 
recruited in district hospitals and tertiary nephrology 
centres. The primary objective of the main trial was to 
determine whether an initial 16 week extended course 
of prednisolone treatment increased the time to first 
relapse in children with steroid sensitive nephrotic 
syndrome compared with the eight week standard 
course. Secondary objectives were to determine 
whether the extended course reduced the relapse 
rate, the proportion of participants who developed 
frequently relapsing nephrotic syndrome or steroid 
dependent nephrotic syndrome, and the requirement 
for second and third line immunosuppressive agents. 
Additionally, we considered whether the extended 
course was associated with an increased incidence 
of corticosteroid related adverse events, including 
behavioural problems. We also performed a cost 
effectiveness analysis by comparing costs and quality 
adjusted life years for the two regimens, and the 
methods and results are reported in supplementary 
appendices 1, 3, and 4.
Methods
Participants
We performed this double blind, placebo controlled, 
randomised controlled trial across 125 UK National 
Health Service district general hospitals and tertiary 
paediatric nephrology centres. Children aged 1-14 
years with a first episode of idiopathic nephrotic 
syndrome were eligible to participate if they had a first 
morning urine protein to creatinine ratio or albumin 
to creatinine ratio greater than 200 mg/mmol; had a 
serum or plasma albumin level less than 25 g/L; had 
not previously received treatment with corticosteroids, 
immunosuppressive or cytotoxic drugs for any form 
of renal disease; and had no evidence of underlying 
systemic disorder or use of drugs known to be associated 
with nephrotic syndrome. We excluded children with 
histological changes other than minimal change 
glomerulonephritis (when renal biopsy had been 
performed), history of poor adherence to treatment, or 
a known allergy to prednisolone.
Interventions and randomisation
Potential participants started prednisolone 60 mg/
m2 daily for four weeks in accordance with routine 
clinical practice. Trial recruitment and randomisation 
took place when the children were thought to be 
corticosteroid sensitive (three consecutive days of zero 
or trace proteinuria on Albustix test; generally between 
14 and 21 days after start of prednisolone treatment). 
We obtained fully informed written consent from the 
parents or guardians and assent from children when 
age appropriate. We then performed randomisation 
online through a secure 24 hour internet based 
randomisation service or by a telephone call to the 
Birmingham Clinical Trials Unit. Participants were 
randomised in a 1:1 ratio to either an extended course 
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of treatment or a standard course of treatment by 
using a minimisation algorithm to ensure balanced 
treatment allocation by ethnicity (South Asian, white, 
or other) and age (5 years or less, 6 years or more). 
The extended treatment group received prednisolone 
60 mg/m2 daily (maximum 80 mg) for four weeks 
followed by 12 weeks of prednisolone treatment on 
alternate days, starting at 60 mg/m2 (maximum 80 mg) 
and tapering by 10 mg/m2 every two weeks (total dose 
3150 mg/m2). The standard treatment group received 
prednisolone 60 mg/m2 daily (maximum 80 mg) for 
four weeks followed by 40 mg/m2 (maximum 60 mg) on 
alternate days for four weeks (total dose 2240 mg/m2). 
In both groups, treatment in the first four weeks was 
open label and then it was blinded in the following 12 
week phase, with matching placebo in the standard 
course (control) group. A central pharmacy dispensed 
the entire course of blinded trial drugs in crushable 
tablet form in blister packs, delivered by courier to the 
family home.
In accordance with routine clinical practice, 
children’s first morning urine was tested for proteinuria 
(Albustix). We provided parents with a diary so that 
they could record urine test results and the drugs 
administered on a daily basis. Parents also used 
the diary to record illnesses and consultations with 
healthcare professionals (such as general practitioners, 
nurses, or hospital emergency department clinicians), 
and details of drugs prescribed or purchased over 
the counter. Families contacted their local trial site if 
the child had a relapse (urine analysis showed three 
consecutive days of 3+ proteinuria or generalised 
oedema in association with 3+ proteinuria) so that 
treatment could be prescribed. We also instructed 
families to call their local site if they had any other 
concerns—for example, if their child had developed 
new adverse events or they had questions about urine 
analysis results.
Trial assessments and data collection
We performed trial visits at 4, 8, 12, and 16 weeks, 
and then at 5, 6, 8, 10, 12, 18, 24, 30, 36, 42, and 
48 months after the children started treatment with 
open label prednisolone. They were followed up for a 
minimum of 24 months and up to a maximum of 48 
months. The trial finished when the last participant had 
completed 24 months of follow-up. At each trial visit, 
we recorded information on relapses, adherence to trial 
treatment, other drug treatments, adverse events, and 
use of healthcare resources. A full clinical assessment 
was performed, including height, weight, and blood 
pressure measurements. Any event that resulted in 
death, was life threatening, required admission to 
hospital or prolonged an existing hospital admission, 
caused persistent or major disability or incapacity, or 
resulted in a congenital anomaly or birth defect was 
considered a serious adverse event. These events were 
reported using specific forms.
Data recorded on case report forms were generally 
not the source data for clinical information. However, 
when self reported patient information on relapses and 
drug changes was taken from diaries and entered onto 
case report forms, these forms were considered to be 
the source data. We did not verify source data taken 
from diaries because the diaries were not retained.
Parents completed three questionnaires at 4 and 
16 weeks, and then at 12, 24, 36, and 48 months: 
the Achenbach child behaviour checklist was used to 
assess behavioural change in eight categories (anxious/
depressed, withdrawn/depressed, somatic complaints, 
social problems, thought problems, attention problems, 
rule-breaking behaviour, and aggressive behaviour), 
and the paediatric quality of life inventory and the child 
health utility 9 dimension were used to assess quality 
of life.18-20
Sample size
The primary analysis was based on a log rank test of 
time to relapse. We expected a relapse rate of 60% at 
one year in the standard course group. To detect an 
absolute difference of 20% (considered a clinically 
meaningful difference by the paediatric nephrologists 
on the study team) in the relapse rate, from 60% in the 
standard course group to 40% in the extended course 
group, with 80% power and α=0.05, we needed 200 
participants. Allowing for a dropout rate of 15%, the 
total number of participants required was 236 (118 in 
each group).
Statistical analysis
The primary outcome measure was the time from 
starting open label prednisolone treatment to first 
relapse. We used Kaplan-Meier survival curves to 
visually present the time to first relapse. We compared 
the primary analysis of time to first relapse between 
groups using a log rank test. A Cox proportional 
hazard model was fitted to obtain a hazard ratio and 
95% confidence intervals. As a secondary analysis, 
we also fitted a Cox proportional hazard model, 
which was adjusted for the minimisation variables 
of ethnicity (South Asian, white, or other) and age 
(5 years or less, 6 years or more). It is unlikely that a 
child will have a relapse while taking corticosteroids; 
however, it is possible for children in the standard 
course group to experience an early relapse in weeks 
9-16 when receiving placebo, which could bias 
the results in favour of the extended course group. 
Corticosteroid dependency could also differ between 
the groups (defined as relapsing while receiving 
corticosteroid treatment or within 14 days of stopping 
the drug). To avoid the potential for bias in these 
situations, we set the relapse time to 18 weeks in 
children who had a relapse before 18 weeks. We also 
performed a secondary analysis of time to first relapse 
using the actual relapse date. Two a priori subgroup 
analyses were carried out for the primary outcome for 
the minimisation variables of ethnicity (South Asian, 
white, or other) and age (5 years or less, 6 years or 
more). We included a treatment group by subgroup 
interaction parameter in the Cox proportional hazard 
model to assess whether there were any differences 
in the treatment effect across the different stratums.
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Secondary outcomes were relapse rate, incidence 
of frequently relapsing nephrotic syndrome and of 
steroid dependent nephrotic syndrome, use of second 
line immunosuppressive drugs, rates of adverse events 
and serious adverse events, behavioural change using 
the Achenbach child behaviour checklist, and quality 
adjusted life years. We compared relapse rates (number 
for each child) using a negative binomial model to 
obtain an incident rate ratio. Categorical data items 
(eg, frequently relapsing nephrotic syndrome, steroid 
dependent nephrotic syndrome) were analysed using a 
χ2 test, and relative risks were produced. We reported 
adverse event data on a Likert scale (none, mild, 
moderate, or severe). These data were dichotomised 
according to whether the participant experienced the 
adverse event or not, and relative risks were reported. 
The number of children who reported a serious adverse 
event was reported. The Achenbach child behaviour 
checklist was analysed using repeated measures 
methods. We converted the exploratory outcomes 
height, weight, body mass index, and blood pressure 
values to standard deviation scores and presented 
them graphically using longitudinal plots, with no 
statistical analysis planned.
We included participants in the analysis according 
to their initial randomised treatment allocation. 
We excluded participants who were found to be 
corticosteroid resistant after randomisation. This is 
not expected to introduce bias because most of the 
dropouts occurred before the start of randomised 
treatment, and clinicians were unaware of the 
treatment assigned to their patients. We describe this 
analysis as intention to treat. A hazard ratio or relative 
risk less than 1 favoured the children who received an 
extended course of treatment. Estimates of treatment 
effects are presented with 95% confidence intervals. 
P values are two tailed with a P value less than 0.05 
considered statistically significant. Analyses were 
carried out using SAS version 9.4 (Cary, NC) or Stata 14 
(StataCorp, College Station, TX).
Patient and public involvement
The trial protocol was reviewed by representatives of the 
UK Nephrotic Syndrome Trust (NeST) and the UK Renal 
Patient Support Group, who provided valuable input 
about trial design, acceptability of trial visit frequency, 
and adverse event monitoring. A NeST representative 
participated on the trial steering committee. After 
publication, the trial results will be disseminated to 
all study collaborators. The plain English summary of 
the study results will be sent to the participants and/or 
their parents through their responsible clinician. The 
summary will also be available on the NeST website 
and the PREDNOS study website (www.birmingham.
ac.uk/prednos).
Results
Participants
Overall, 237 participants aged 1-14 years were recruited 
from 86 centres between July 2011 and October 2014; 
119 were randomised to an extended course of treatment 
and 118 to a standard course of treatment. Fourteen (five 
in the extended course group and nine in the standard 
course group) were withdrawn early after randomisation 
because of loss of corticosteroid sensitivity, leaving an 
intention to treat analysis population of 223 (114 in 
the extended course group and 109 in the standard 
course group). Figure 1 shows the patient flow through 
the trial. When participants withdrew consent or were 
lost to follow-up, data collected up until that point were 
included in the analysis.
Baseline characteristics did not differ between the 
extended course and standard course groups (table 1). 
Most of the intention to treat population were boys (65%, 
n=146), 65% (n=145) were aged less than 6 years, and 
20% (n=44) were of South Asian origin. Eighty six (39%) 
did not complete their course of trial drugs. This was 
more common in the standard course group (extended 
course 32/114 (28%) v standard course 54/109 (50%); 
P=0.001) and the main reason was relapse while double 
blind trial drugs were being administered. Adherence to 
trial drugs was high; 13% (n=29) reported missed doses 
and most of these patients reported missing only one 
or two doses. Attendance rates for follow-up trial visits 
were high, as were submission rates of clinical data 
and participant questionnaires (>90% of expected data 
received at each time point).
Primary outcome
No statistically significant difference was found in 
the primary outcome measure of time to first relapse 
between the extended course and standard course 
groups (fig 2; hazard ratio 0.87, 95% confidence 
interval 0.65 to 1.17; log rank P=0.28). The median 
time to first relapse was 139 (interquartile range 90-
179) days for the extended course group versus 87 
(64.5-134) days for the standard course group. Eighty 
per cent (n=179) of participants reported a relapse 
during trial follow-up (extended course 91/114 (80%) 
v standard course 88/109 (81%); difference −1%, 95% 
confidence interval −11% to 10%; table 2).
Prespecified subgroup analyses for the primary 
outcome for ethnicity (South Asian, white, or other) 
and age (5 years or less, 6 years or more) showed no 
clear evidence to suggest that the treatment effect 
differed between the participant subgroups. We found 
some evidence (P for interaction=0.08) that time to first 
relapse was increased in participants in the extended 
course group aged 5 years or less (hazard ratio 0.72, 
95% confidence interval 0.50 to 1.05) compared with 
participants aged 6 years or more. In participants aged 
6 years or more, time to first relapse was increased in 
those in the standard course group (1.26, 0.77 to 2.07).
Secondary outcomes
The total number of relapses in each participant 
ranged from zero to 15; nine participants in the 
extended course group and eight in the standard 
course group had 10 or more relapses. We found 
no differences in the mean number of relapses, the 
proportion developing frequently relapsing or steroid 
dependent nephrotic syndrome, or the number 
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requiring alternative immunosuppressive treatment. 
The total dose of prednisolone received during the 
trial (after completing the course of trial drugs) was 
not statistically significantly different between the two 
treatment groups (table 2).
Adverse events and behaviour
Table 3 shows the cumulative incidence of adverse 
events over the 24 months of follow-up. We found no 
differences between the two groups for any of these 
adverse events except for poor behaviour reported by 
parents (yes or no), which was more common in the 
standard course group. However, when we analysed 
the detailed quantitative behavioural data collected 
using the Achenbach child behaviour checklist we 
found no differences in behaviour score (P=0.28) or the 
proportion of participants reporting normal checklist 
scores at any time point during the trial.
Randomised
Extended course treatment
237
119
Standard course treatment
118
Participants steroid resistant9
109
Participants steroid resistant5
114
16 weeks
Withdrew consent
Patients had disease relapse
3
33
110
32 participants discontinued trial drug early
Discontinued because of relapse
Discontinued because of inability to take trial drug
Did not start trial drug because parents withdrew
  consent but happy for participant to be
  followed up
29
3
1
54 participants discontinued trial drug early
Discontinued because of relapse
Discontinued because of inability to take trial drug
Did not start trial drug because could not
  swallow tablet
50
4
1
16 weeks
Withdrew consent*
Withdrew because of compliance issue during
  open label phase
Patients had disease relapse
3
1
62
105
Six months
Withdrew consent†
Patients had disease relapse
3
11
102
12 months
Withdrew consent
Patients had disease relapse
1
11
101
12 months
Withdrew consent
Lost to follow-up
Patients had disease relapse
1
1
16
108
24 months
Withdrew consent
Lost to follow-up
Patients had disease relapse
Time points are from start of open label treatment
* Two patients had discontinued their trial drug
† Two patients had discontinued their trial drug because of relapse
1
1
4
106
Six months
Patients had disease relapse37
110
24 months
Patients had disease relapse3
101
4 weeks
Withdrew consent1
113
4 weeks
109
Fig 1 | CONSORT diagram of participant flow through trial
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Serious adverse events
Forty six participants reported 67 serious adverse 
events (extended course 19/114 (17%) v standard 
course 27/109 (25%); P=0.13). Serious adverse events 
most commonly related to admission for disease 
relapse or bacterial infection. We considered six serious 
adverse events in the extended course group and five in 
the standard course group to be drug related, although 
none resulted in discontinuation of the trial drug. The 
one death due to unintentional injury was unrelated to 
the trial.
Exploratory outcomes
The mean height, weight, and body mass index 
z scores did not differ between the two treatment 
groups at any time point throughout the trial period. 
We found a progressive increase in height z score and 
decrease in body mass index z score over the trial 
period (supplementary figs 1 and 2). No differences 
were found in mean systolic and diastolic blood 
pressure between the two treatment groups at any time 
point throughout the trial, with a trend to reduction 
in z score with increasing time after presentation 
(supplementary fig 3).
Cost effectiveness analysis
Supplementary appendices 1, 3, and 4 report full 
details of the economic evaluation. In brief, we found 
the extended course of treatment to be cheaper than 
the standard course after allowing for all primary 
care, secondary care, and prescription costs over 24 
months. Furthermore, the extended course produced 
a small incremental gain in quality of life compared 
with the standard course. These findings mean that the 
extended course was a cost effective use of healthcare 
resources when conventional rules of cost effectiveness 
were applied.
Discussion
The PREDNOS trial recruited UK children with steroid 
sensitive nephrotic syndrome and compared an initial 
extended 16 week course of prednisolone treatment 
with the standard eight week course described by the 
International Study of Kidney Disease in Children. 
The results did not show any clinical benefit on key 
primary and secondary clinical endpoints. We found 
no statistically significant difference between the two 
treatment groups in the outcome measures: time to first 
relapse of nephrotic syndrome; incidence of any relapse 
or the number of relapses experienced; the proportion 
of participants who went on to develop frequently 
relapsing or steroid dependent nephrotic syndrome; 
or the requirement for alternative non-corticosteroid 
immunosuppressive treatment. Confidence intervals 
for the incidence of any relapse excluded clinically 
important benefit. Subgroup analyses showed no clear 
evidence that the treatment effect differed according to 
ethnicity or age, although the trial was not powered to 
detect differences in subgroups.
Although there is no evidence that an extended 
course of prednisolone treatment statistically signifi-
cantly reduces clinical endpoints, the direction of the 
effect was to delay the time to relapse. We found some 
evidence that an extended course of prednisolone 
reduced healthcare resource use in the first two years 
and resulted in a small improvement in quality of 
Table 1 | Baseline characteristics of intention to treat population. Values are numbers (percentages) unless stated 
otherwise
Characteristics Extended course group (n=119) Standard course group (n=118) Total (n=237)
No of corticosteroid sensitive  
participants
114 109 223
Mean (SD) age (years) 5.1 (3.2) 4.7 (2.9) 4.9 (3.1)
Age (years):
 1-2 28 (25) 29 (27) 57 (26)
 3-5 45 (39) 43 (39) 88 (39)
 6-11 35 (31) 34 (31) 69 (31)
 12-17* 6 (5) 3 (3) 9 (4)
Age (years)†:
≤5 73 (64) 72 (66) 145 (65)
≥6 41 (36) 37 (34) 78 (35)
Boys 68 (60) 78 (72) 146 (65)
Ethnicity†:
 South Asian 23 (20) 21 (19) 44 (20)
 White 75 (66) 73 (67) 148 (66)
 Other or not stated 16 (14) 15 (14) 31 (14)
Median (interquartile range) body 
mass index centile 
90.0 (69.5-97.5) 85.3 (66.3-97.3) 87.5 (66.6-97.3)
Body mass index centile:
 Underweight (<5th) 0 (0) 2 (2) 2 (1)
 Healthy (5th-84th) 48 (42) 52 (48) 100 (45)
 Overweight (85th-95th) 24 (21) 19 (17) 43 (19)
 Obese (≥95th) 42 (37) 36 (33) 78 (35)
Mean (SD) open label daily predniso-
lone dose (mg/m2) 58.0 (6.8) 58.5 (5.9) 58.2 (6.4)
*Participants were eligible for the trial if they were aged 1-14 years at time of diagnosis.
†Minimisation variable.
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life. Combined in a cost effectiveness analysis, these 
findings provide evidence that an extended course of 
treatment is a cost effective use of healthcare resources.
Strengths and weaknesses of this study
The randomised, double blind, placebo controlled trial 
design ensured a low risk of selection, performance, 
detection, and selective reporting bias. The unselected 
trial population with broad inclusion criteria that was 
recruited from 86 centres across the UK included 44 
(20%) participants from the South Asian community. 
The trial was therefore representative of UK children 
presenting with steroid sensitive nephrotic syndrome. 
The inclusion of a substantial proportion of participants 
of South Asian origin is of particular importance because 
of the increased incidence of the disease in this group. 
In addition, the UK South Asian population is generally 
under-represented in clinical trials, with recruitment 
posing several challenges.21
We managed to recruit around one third of all 
UK children who presented with steroid sensitive 
nephrotic syndrome over the trial period, which 
indicates a high level of acceptance of the trial among 
patients and clinicians. We used internationally 
recognised definitions of disease outcomes from the 
International Study of Kidney Disease in Children. 
We also chose a primary outcome measure that was 
believed to be of great clinical importance by clinicians 
and patient advisors and was consistent with the 
outcome measures used in many other studies. We 
systematically produced data on adverse effects related 
to corticosteroid treatment; these data are clinically 
relevant and of great importance to families but are 
often ignored. Baseline features were well balanced 
and the dropout rate was low and rate of completion 
of visits high.
Possible weaknesses include the potential exclusion 
of young children who were unable to take the trial 
drug, which was provided as a crushable tablet, rather 
than a suspension or in soluble or dispersible form. 
We found 14 participants to be steroid resistant after 
randomisation but before any difference in treatment 
regimen started, and we withdrew these children from 
the trial. In practice, these patients would not receive 
the extended or standard course of treatment, and so 
the intention to treat analysis was not compromised. 
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Fig 2 | Time to first relapse in participants receiving extended or standard course of prednisolone treatment
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The mean age of participants was 4.9 years, which 
is higher than the median age of presentation in the 
International Study of Kidney Disease in Children 
(3 years). The mean age in our trial is, however, 
comparable to the median ages of 4.2-6.7 years in 
the three most recent randomised controlled trials 
of corticosteroid treatment in children with steroid 
sensitive nephrotic syndrome.
Comparison with other studies
The Kidney Disease: Improving Global Outcomes 2012 
treatment recommendations were based on six trials 
that were reported before the start of the PREDNOS 
trial, but they all had methodological deficiencies.10-15 
None was adequately blinded and there were additional 
concerns about selection, performance, detection, and 
attrition biases. While we conducted the PREDNOS trial, 
two randomised controlled trials were reported that 
compared shorter and longer corticosteroid regimens. 
One of these trials was a high quality Japanese study 
that compared eight weeks of prednisolone treatment 
with six months of treatment.22 23 Similar to PREDNOS, 
the findings showed no benefit of treatment extension.
Our outcome data are similar to those reported in 
previous studies; in particular the overall proportion 
of participants who had a relapse and the rate of 
frequently relapsing nephrotic syndrome. Previous 
studies have been inconsistent in the monitoring 
and reporting of adverse events associated with 
using corticosteroids. However, meta-analyses have 
consistently shown no difference in risk of adverse 
events between an eight week course of prednisolone 
treatment and longer duration regimens. Similar to 
these findings, we found no differences in adverse 
events between the extended course and standard 
course groups in PREDNOS; one exception was poor 
behaviour reported by parents, which was more 
common in the standard course group. However, 
despite this difference in reported behaviour, when 
parents completed the Achenbach child behaviour 
checklist, no statistically significant differences in 
behaviour scores were detected that might indicate a 
clinical concern. Consistent with current UK clinical 
practice, in this trial we did not routinely perform 
formal slit lamp ophthalmic assessment, regular blood 
tests, or dual energy x ray absorptiometry scans to 
Table 2 | Secondary outcome measures in extended course and standard course groups. Values are numbers 
(percentages) unless stated otherwise
Secondary outcome measures
Extended course 
group
Standard course 
group
Estimate (extended v short 
course) (95% CI) P value
Relapse n=114 n=109
No of relapses 454 394 —
No of participants who had a relapse 91 (80) 88 (81) 0.87* (0.65 to 1.17) 0.28
Mean (SD) No of relapses for each participant 3.98 (3.30) 3.61 (3.25) 1.09† (0.86 to 1.39) 0.46
No of participants who had FRNS 60 (53) 55 (50) 1.04‡ (0.81 to 1.35) 0.75
No of participants who had SDNS 48 (42) 48 (44) 0.96‡ (0.71 to 1.29) 0.77
Second line immunosuppressive drugs
No of participants who received  
immunosuppressant drugs
62 (54) 61 (56) 0.97† (0.77 to 1.23) 0.81
Type of immunosuppressant drug:
 Ciclosporin 4 (4) 6 (6) —
 Tacrolimus 18 (16) 8 (7) —
 Levamisole 34 (30) 35 (32) —
 Cyclophosphamide 29 (25) 31 (28) —
 Mycophenolate mofetil 15 (13) 13 (12) —
 Rituximab 1 (1) 5 (5) —
Corticosteroid dose n=94 n=90 —
 Mean (SD) total prednisolone dose (mg)‡ 6674.1 (4998.2) 5474.6 (3697.3) Mean difference=1199.5  
(−83.8 to 2482.8)
0.07
A ratio less than 1, and a negative mean difference, favours the extended course group.
FRNS=frequently relapsing nephrotic syndrome; SDNS=steroid dependent nephrotic syndrome.
*Hazard ratio.
†Incident rate ratio.
‡Relative risk.
‡Total dose received during trial (after completion of trial drug).
Table 3 | Cumulative incidence of adverse events over 24 months of follow-up. Values are numbers (percentages) unless 
stated otherwise
Adverse event Extended course group (n=114) Standard course group (n=109) Relative risk (95% CI)
Cushingoid facies 83 (73) 78 (72) 1.02 (0.88 to 1.19)
Striae 14 (12) 7 (6) 1.92 (0.81 to 4.54)
Hypertrichosis 45 (39) 41 (38) 1.05 (0.77 to 1.45)
Acne 12 (11) 7 (6) 1.64 (0.68 to 3.99)
Increased appetite 106 (93) 103 (94) 1.00 (0.94 to 1.07)
Poor behaviour 94 (82) 101 (93) 0.90 (0.82 to 0.98)
Glycosuria 19 (17) 14 (13) 1.34 (0.72 to 2.48)
Cataract 1 (1) 1 (1) 0.96 (0.06 to 15.00)
Abdominal pain 49 (43) 51 (47) 0.91 (0.69 to 1.20)
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assess bone mineral density. These tests have been 
included in the protocols of other recent high quality 
randomised controlled trials; the overall incidence of 
cataract, major persistent biochemical abnormality, 
and bone mineral density abnormality was low.
Our data suggest a possible advantage of an extended 
course of prednisolone treatment in children younger 
than 6 years, although the trial was not powered to 
detect differences in subgroups. This advantage has 
also been identified in other randomised controlled 
trials23 and warrants further investigation. We suggest 
an individual patient data meta-analysis, particularly 
as several studies have shown that children aged less 
than 6 years generally have a higher risk of frequently 
relapsing nephrotic syndrome and steroid dependent 
nephrotic syndrome.11 23-25 The shift of evidence 
away from the use of an extended course of treatment 
back to a standard course of treatment raises the 
problem of whether further studies should investigate 
if corticosteroid courses can be reduced further in 
steroid sensitive nephrotic syndrome. This subject 
has been dealt with in an early randomised controlled 
trial, which showed the relapse rate and incidence of 
frequently relapsing nephrotic syndrome were higher 
in children who received a shorter course of treatment 
rather than a standard course of treatment.26 However, 
in common with many of the earlier studies in this 
disease group, the trial was at risk of several biases.
The supplementary material reports the economic 
evaluation, which shows the extended course of 
treatment to be cost effective. We found healthcare costs 
in the extended course group were reduced because 
of fewer primary care visits and hospital admissions, 
lower costs of some drugs, and increased quality of 
life measured at various time points. These economic 
observations are compatible with the clinical outcomes 
because they act in the same direction as the increase in 
time to relapse with the extended course of treatment. 
Cost effectiveness analyses focus on the combined ratio 
of costs and outcomes. In our analysis, the extended 
course was cheaper and produced a gain in quality of 
life, therefore it offered a cost effective use of resources.
Conclusions and policy implications
The PREDNOS trial provides evidence that an extended 
16 week course of prednisolone treatment will not 
improve important clinical endpoints compared with 
the standard eight week course of treatment. However, 
depending on the decision making criteria, extended 
course treatment could offer a cost effective use of 
healthcare resources. Concerns about adverse events 
from extended prednisolone treatment were not 
supported.
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